Bonafide Health has launched Noctera, a hormone-free, melatonin-free supplement targeting sleep disruptions caused by hormonal changes during the menopause transition.
Rather than using sedatives or melatonin, Noctera works through GABAergic and glutamate pathways – rebalancing the brain’s calming and excitatory signals that get disrupted as estrogen levels decline. The continuous-release formula combines magnesium glycinate, GABA, L-theanine, and SAMe.
Bonafide backs the product with data from a randomized, double-blind, placebo-controlled trial in perimenopausal and postmenopausal women with moderate-to-severe sleep disturbances. Key findings include 88% of participants moving to “within normal limits” for sleep disturbances within three weeks, an average increase in sleep duration of 40 minutes, and 89% of women finding it easier to fall back asleep after nocturnal waking.
“Declining estrogen levels during the menopause transition affect the balance of both GABA, a calming neurotransmitter, and glutamate, an excitatory one,” said Dr. Alyssa Dweck, Bonafide’s Chief Medical Officer and co-author of the Noctera studies. “This imbalance has direct effects on sleep, specifically associated with the frequent nocturnal awakenings and difficulty falling back asleep during this time of life.”
Bonafide, which says it’s trusted by more than 13,000 doctors, has built its brand around clinically studied, hormone-free menopause symptom relief. Noctera adds to a portfolio positioning the company as a supplement-based alternative for women who want evidence-backed options outside of HRT.
